The KLOW peptide blend is the GLOW blend (GHK-Cu, BPC-157 and TB-500) with a fourth peptide added: KPV, a small anti-inflammatory fragment of the hormone alpha-MSH.[18][1] It is marketed for skin, injury recovery and inflammation and sold as a research-use-only vial. No human or animal study has tested KLOW as a blend, and FDA found no human data on KPV by any route.[17][5]
This guide covers what’s in KLOW, what KPV adds, how KLOW compares with GLOW, the evidence, side effects, dosage and the 2026 regulatory changes. For the three shared ingredients in depth, see our GLOW peptide blend guide, and for related compounds, the healing and skin peptides hub.
What is the KLOW peptide blend?
Sellers commonly list KLOW as an 80 mg vial: 50 mg of GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV.[19] One seller labels it “for research use only” and “not for human consumption”, and notes that none of its ingredients is FDA-approved.[18] Those amounts come from seller listings, not from any study.
| Ingredient | What it is | Best human evidence |
|---|---|---|
| GHK-Cu | Copper-binding tripeptide found in blood | Small topical skin trials[14] |
| BPC-157 | 15-amino-acid peptide based on a stomach protein | Small uncontrolled pilots[12] |
| TB-500 | Fragment of thymosin beta-4[16] | None[5] |
| KPV | Three-amino-acid fragment of alpha-MSH[1] | None[5] |
What is KPV?
KPV is a tripeptide made of three amino acids: lysine, proline and valine. It is the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), and it keeps that hormone’s anti-inflammatory effects without its skin-darkening effect.[1]
What the research shows, all in mice or cells:
- Colitis: KPV given in drinking water was absorbed by the gut through a transporter called PepT1 and reduced chemically induced colitis in mice.[2]
- Survival in severe colitis: in a German study, KPV sped recovery from colitis, and in mice with a defective melanocortin receptor it prevented all deaths in the treated group.[3]
- Targeted delivery: KPV packed into nanoparticles and taken by mouth eased ulcerative colitis in mice.[4]
FDA found no clinical studies of KPV in people, no animal toxicity studies, and no adverse event reports. In a lab test on human skin, KPV did not pass through the skin well.[5]
KLOW vs GLOW
| GLOW | KLOW | |
|---|---|---|
| Ingredients | GHK-Cu, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500, KPV |
| Typical listed vial | 70 mg | 80 mg[19] |
| Marketed for | Skin, hair, recovery | Skin, recovery, inflammation and gut |
| Studied as a blend? | No[17] | No[17] |
| Human data on the added peptide | Not applicable | None for KPV[5] |
Because KPV has no human data, KLOW is not better supported by evidence than GLOW. It adds a fourth ingredient whose effects in people are unknown. The only animal study combining two of the shared ingredients, BPC-157 and TB-500, found no added benefit from combining them.[13]
KLOW peptide benefits: claims vs evidence
| Claimed benefit | What the evidence shows |
|---|---|
| Less inflammation, gut healing | KPV reduced colitis in mice[2][3]; no human studies |
| Skin quality and collagen | GHK-Cu topical trials are few and small[14]; no injected human trials[15] |
| Faster recovery from injuries | BPC-157 studies are almost all in animals[12] |
| Combined effect | Never tested; combining BPC-157 and TB-500 showed no extra benefit in rats[13] |
What users report
Side effects and safety
No study has measured KLOW’s side effects. For the shared ingredients, see the GLOW safety section, which covers FDA adverse event reports including skin and gum darkening, and possible blood-clotting and liver signals in animal studies of BPC-157.[5]
For KPV specifically:
- No human safety data and no toxicity studies in animals.[5]
- Immune reactions and impurities are FDA’s main concern for all injectable peptides in this group.[9]
- More ingredients, more unknowns: a 2026 review warns that unregulated injectable peptides carry risks from contamination and dosing errors, as well as theoretical risks such as abnormal blood vessel growth.[21]
KLOW peptide dosage
No dose of KLOW, or of KPV, has been studied in people.[5][17] In mouse colitis studies, KPV was given by mouth in drinking water or nanoparticles, not by injection.[2][4] For human doses studied for the three GLOW ingredients, see the GLOW dosage section. To convert a vial’s milligrams into syringe units, use our peptide calculator.
Is KLOW FDA approved or legal?
- Not FDA-approved. BPC-157, TB-500 and KPV are not part of any approved drug.[5]
- 2023: FDA listed KPV, BPC-157, TB-500 and injectable GHK-Cu among substances that may pose significant safety risks in compounding.[9]
- April 2026: after the nominations were withdrawn, FDA removed them from that list, which is not an approval.[9][10]
- July 2026: FDA’s compounding advisory committee reviewed KPV for wound healing and inflammatory conditions, alongside BPC-157 and TB-500.[7] FDA recommended against all three, but the committee reportedly voted 8 to 6 in favor of each.[6][8] The vote is not binding, and no rule had followed as of our last review.
- Sport: WADA bans BPC-157 and TB-500 at all times. KPV is not named on the 2026 list.[11][22]
This is general information, not legal advice.